U.S. Pharmacists Report on COVID-19 Vaccine Safety Issues

U.S. Pharmacist publishes its “COVID-19 Vaccine Safety Update” noting that the adverse effect (AE) profile of the two mRNA COVID-19 vaccines (Pfizer and Moderna) and the recombinant protein COVID-19 vaccine (Novavax) that are currently available markedly differ. mRNA vaccines are associated with myocarditis/pericarditis. What about any connection of the mRNA vaccines with Bell’s palsy? The data is conflicted. This publication notes that Guillain-Barré syndrome is not likely an AE of mRNA COVID-19 vaccines. Yet TrialSite can report peer-reviewed documented incidence of GBS in the Scientific Publications Directory. Anaphylaxis, severe, life-threatening allergic reaction and lymphadenopathy, swelling of lymph nodes which can be secondary to bacterial, viral, or fungal infections, autoimmune disease, and malignancy,  are systemic immunological AEs associated with the mRNA COVID-19 vaccines. Novavax COVID-19 vaccine–related symptoms involve more traditional systemic reactions. The authors point to the role of Pharmacists in promoting public health by dispelling misinformation about COVID-19 vaccine safety, fulfilling their role as mandatory reporters of AEs, and educating the public about the proven benefits of vaccination.

How many COVID-19 vaccines are available in the United States?